Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2021
DOI:
https://doi.org/10.33321/cdi.2022.46.77Keywords:
Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance surveillance, Enterococcus faecium, Enterococcus faecalis, vancomycin resistant enterococci (VRE), bacteraemiaAbstract
From 1 January to 31 December 2021, forty-eight institutions around Australia participated in the Australian Enterococcal Surveillance Outcome Programme (AESOP). The aim of AESOP 2021 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the Enterococcus faecium isolates. Of the 1,297 unique episodes of enterococcal bacteraemia investigated, 94.4% were caused by either E. faecalis (54.1%) or E. faecium (40.3%). Ampicillin resistance was detected in one E. faecalis isolate and in 89.3% of E. faecium isolates. Vancomycin non-susceptibility was not detected in E. faecalis but was detected in 37.9% of E. faecium. Overall, 39.6% of E. faecium harboured the vanA and/or vanB genes. For the vanA/vanB positive E. faecium isolates, 35.8% harboured the vanA gene and 64.2% the vanB gene. Although the percentage of vancomycin-resistant E. faecium bacteraemia isolates was significantly lower than that reported in the 2020 AESOP report (presumably due to the COVID-19 elective surgery restrictions placed on hospitals), it remains substantially higher than that recorded in most European countries. Isolates of E. faecium consisted of 73 multi-locus sequence types (STs); 77.2% of isolates were classified into seven major STs each containing more than ten isolates. All major STs belonged to clonal cluster (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. The major STs (ST17, ST1424, ST796, ST78, ST80, ST1421 and ST555) were found across most regions of Australia. The predominant ST was ST17 which was identified in all regions except the Northern Territory. Overall, 46.5% of isolates belonging to the seven major STs harboured the vanA or vanB gene. The AESOP 2021 has shown that enterococcal bacteraemia episodes in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin resistant vanA- or vanB-positive E. faecium which have limited treatment options.
Downloads
References
Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51. doi: https://doi.org/ 10.1111/1469-0691.12236.
Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70. doi: https://doi.org/10.1016/j.diagmicrobio.2006.12.022.
Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65. doi: https://doi.org/10.1128/CMR.3.1.46.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. doi: https://doi.org/10.1086/595011.
Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC, Australian Group on Antimicrobian Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.
Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5. doi: https://doi.org/10.1097/PAT.0000000000000038.
Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52(3):897–905. doi: https://doi.org/10.1128/JCM.03286-13.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Wayne, PA: CLSI; 16 February 2022.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. Basel: EUCAST; 1 January 2022. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf.
Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed on 3 Jun 2016.] Available from: https://github.com/tseemann/nullarbor.
European Centre for Disease Prevention and Control (ECDC). Data from the ECDC Surveillance Atlas – Antimicrobial resistance. [Webpage.] Solna: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc.
Coombs GW, Pearson JC, Daly DA, Le TT, Robinson JO, Gottlieb T et al. Australian Enterococcal Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E320–6.
Coombs GW, Daley DA, Lee YT, Pang S, Pearson JC, Robinson JO et al. Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014. Commun Dis Intell Q Rep. 2016;40(2):E236–43.
Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2015. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00015-5.
Coombs GW, Daley DA, Lee YT, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00020-9.
Coombs GW, Daley DA, Lee YT, Pang S. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.42.
Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.19.
Coombs GW, Daley DA, Mowlaboccus S, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.72.
Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.17.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
